ATE166650T1 - Spiroazacyclischderivate als substanz p antagonisten - Google Patents

Spiroazacyclischderivate als substanz p antagonisten

Info

Publication number
ATE166650T1
ATE166650T1 AT94909413T AT94909413T ATE166650T1 AT E166650 T1 ATE166650 T1 AT E166650T1 AT 94909413 T AT94909413 T AT 94909413T AT 94909413 T AT94909413 T AT 94909413T AT E166650 T1 ATE166650 T1 AT E166650T1
Authority
AT
Austria
Prior art keywords
pct
compounds
antagonists
substance
sec
Prior art date
Application number
AT94909413T
Other languages
English (en)
Inventor
Manoj C Desai
Lawrence A Vincent
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE166650T1 publication Critical patent/ATE166650T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
AT94909413T 1993-03-04 1993-12-10 Spiroazacyclischderivate als substanz p antagonisten ATE166650T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2638293A 1993-03-04 1993-03-04

Publications (1)

Publication Number Publication Date
ATE166650T1 true ATE166650T1 (de) 1998-06-15

Family

ID=21831515

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909413T ATE166650T1 (de) 1993-03-04 1993-12-10 Spiroazacyclischderivate als substanz p antagonisten

Country Status (13)

Country Link
US (1) US5688806A (de)
EP (1) EP0687268B1 (de)
JP (1) JP2832754B2 (de)
CN (1) CN1099035A (de)
AT (1) ATE166650T1 (de)
AU (1) AU6226494A (de)
CA (1) CA2157117C (de)
DE (1) DE69318854T2 (de)
DK (1) DK0687268T3 (de)
ES (1) ES2116587T3 (de)
FI (1) FI105916B (de)
IL (1) IL108769A0 (de)
WO (1) WO1994020500A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5696267A (en) * 1995-05-02 1997-12-09 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
WO1997019084A1 (en) * 1995-11-23 1997-05-29 Merck Sharp & Dohme Limited Spiro-piperidine derivatives and their use as tachykinin antagonists
GB9603136D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
CZ293759B6 (cs) * 1996-03-14 2004-07-14 Warner-Lambert Company Substituovaná cyklická aminokyselina, její použití a farmaceutický prostředek na její bázi
NZ332777A (en) * 1996-06-21 2000-06-23 Merck Sharp & Dohme 3,6-bi-phenyl substituted spiro-piperidine derivatives
GB9613969D0 (en) * 1996-07-03 1996-09-04 Merck Sharp & Dohme Therapeutic agents
ATE320432T1 (de) * 1996-09-25 2006-04-15 Merck Sharp & Dohme Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten
GB9625843D0 (en) * 1996-12-12 1997-01-29 Merck & Co Inc Phenyl spiroethercycloalkyl tachykinn receptor antagonists
US5929094A (en) * 1996-10-25 1999-07-27 Merck & Co., Inc. Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
US5789422A (en) * 1996-10-28 1998-08-04 Schering Corporation Substituted arylalkylamines as neurokinin antagonists
US5945428A (en) * 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
JP2001504853A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 物質使用障害の治療のためのｎｋ−１受容体拮抗薬の使用
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
GB9711114D0 (en) * 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
US7101547B1 (en) 1999-01-22 2006-09-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
GB9902881D0 (en) * 1999-02-09 1999-03-31 Merck Sharp & Dohme Therapeutic agents
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001032625A1 (en) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
WO2001046415A1 (en) * 1999-12-21 2001-06-28 Takeda Chemical Industries, Ltd. Novel tachykinin-like polypeptides and use thereof
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (de) * 2000-09-28 2003-03-26 Pfizer Products Inc. Ein NK-3 rezeptorantagonisten und ein ZNS-penetrierende NK-1 rezeptorantagonisten enthaltende Zusammensetzung zur Behandlung von Depression und Angst
KR20040029375A (ko) * 2001-07-20 2004-04-06 화이자 프로덕츠 인코포레이티드 개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한ｎｋ-1 수용체 길항제의 용도
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
RU2387647C9 (ru) * 2004-08-20 2011-05-27 Таргасепт, Инк. Применение n-арилдиазаспироциклических соединений для лечения зависимостей
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (de) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte hemmung der hepatitis b-virus (hbv)-genexpression mittels kurzer interferierender nukleinsäure (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (de) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
EP2699567A1 (de) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Hemmer des insulinähnlichen wachstumsfaktor-1-rezeptors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (de) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Sina-zusammensetzungen
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (de) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituierte imidazopyridine als hdm2 inhibitoren
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
CA3217403A1 (en) * 2021-05-03 2022-11-10 Prafulkumar CHOVATIA Orexin receptor agonists and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273659A1 (de) * 1986-12-27 1988-07-06 Takeda Chemical Industries, Ltd. Azaspiroverbindungen, ihre Herstellung und Verwendung
ATE122353T1 (de) * 1987-10-05 1995-05-15 Yamanouchi Pharma Co Ltd Heterozyklische spiroverbindungen und ihre herstellung.
EP0360390A1 (de) * 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactamderivate
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5075317A (en) * 1989-06-21 1991-12-24 Fisons Corporation Spirofurane derivatives
ES2065175T3 (es) * 1991-03-01 1995-02-01 Pfizer Derivados de 1-azabiciclo(3.2.2)nonan-3-amina.
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
ES2116587T3 (es) 1998-07-16
IL108769A0 (en) 1994-06-24
US5688806A (en) 1997-11-18
FI941022L (fi) 1994-09-05
EP0687268B1 (de) 1998-05-27
DK0687268T3 (da) 1998-10-12
DE69318854T2 (de) 1998-10-08
JP2832754B2 (ja) 1998-12-09
CN1099035A (zh) 1995-02-22
JPH08503226A (ja) 1996-04-09
FI105916B (fi) 2000-10-31
DE69318854D1 (de) 1998-07-02
CA2157117C (en) 1999-01-05
AU6226494A (en) 1994-09-26
CA2157117A1 (en) 1994-09-15
FI941022A0 (fi) 1994-03-03
EP0687268A1 (de) 1995-12-20
WO1994020500A1 (en) 1994-09-15

Similar Documents

Publication Publication Date Title
DE69318854D1 (de) Spiroazacyclischderivate als substanz p antagonisten
MX9203053A (es) Derivados de aza nor bornano.
PT641328E (pt) Derivados aza-biciclicos em ponte como antagonistas da substancia p
BR1100086A (pt) Derivados de fluoralcóxibenzilamino de heterocìclos contendo nitrogênio
FI942187A0 (fi) Asyklisiä etyleenidiamiinijohdannaisia aine P-reseptoriantagonisteina
DK0675886T3 (da) Aminomethylensubstituerede ikke-aromatiske heterocykler og deres anvendelse som substance P-antagonister
MX9205242A (es) Compuestos heterociclicos que contienen nitrogeno triciclico fusionado.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee